Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female smoking and non-smoking subjects of 18 to 65 years of age (inclusive)
Patients diagnosed with non-chronic migraine with or without aura of duration of at least 12 months prior to the study start
Patient diagnosed with migraine (according to the International Headache Society categories 1.1 and with equal to/more than 3 and equal to/ less than 12 migraine attacks per 4 weeks for each of the last 6 months preceding the Screening
Patients willing to abstain from activities that require focused attention, e.g. driving a car or other vehicles, operating machines or engaging in potentially dangerous activities that require focused attention and intact physical balance
You may not be if
Patients diagnosed with basilar, ophthalmoplegic or hemiplegic migraine as shown in the current/past medical history.
Patients having an experience of non-migraine headaches on more than 6 days per 4 weeks in the past 6 months prior to study start
Patients receiving regular treatment during the four (4) weeks preceding the Baseline with psychoactive drugs (e.g. hypnotics, benzodiazepines, neuroleptics) except antidepressants (eg. SSRIs, SNRIs, Tri- or Tetracyclics).
Patients receiving migraine prevention medications during past three (3) months preceding Baseline
Patients receiving topiramate as migraine prevention medication during past six (6) months preceding Baseline
Patients receiving metamizole as acute treatment of migraine during past three (3) months preceding Baseline
Patients using (or having used within four (4) weeks before the treatment start) drug treatments that are potent inhibitors of OATP transporters (e.g. rifampin).
Any psychiatric condition (e.g., schizophrenia, dementia, bipolar disorder) as shown in the past medical history prior to study start
Patients with recent (within the last three \[3\] years prior to study start) and/or recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting, palpitations, orthostatic hypotension etc.).
Pregnant or nursing (lactating) women. Baselines (1 and 2).
Clareo Health | A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
